995-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study
Bibliographic record
Abstract
The Canadian LMC Diabetes Registry will evaluate real-world clinical outcomes in GLP-1 RA naïve patients with T2D who initiate once weekly semaglutide as part of their usual diabetes therapy in the first year of semaglutide availability in Canada. Primary outcome is change in A1C at 3 - 6 months follow-up. In this interim retrospective analysis of the first six months of semaglutide availability, 542 patients who initiated semaglutide were eligible (37% on 1.0 mg dose and 63% on 0.5 mg dose). They had a mean age of 57.3 ± 10.1 years, T2D duration of 12.0 ± 7.4 years, and baseline A1C of 8.23 ± 1.34%. At 3-6 months follow-up, 466 patients who remained on-treatment showed an A1C reduction of 0.88 ± 1.15% (p<0.01), with 36% of patients achieving an A1C reduction ≥1.0% and 43% of patients achieving A1C ≤7.0%. Similar benefit in A1C lowering was seen in subgroups based on prior diabetes therapy, concomitant insulin use and prior use of DPP-4i (Figure). Mean weight reduction was 3.1 ± 3.6 kg and 23.6% of patients achieved a weight loss ≥ 5%. Reductions were also seen for systolic BP (5.1 ± 13.0 mmHg, p<0.01), diastolic BP (2.2 ± 9.3 mmHg, p<0.01) and alanine aminotransferase (1.7 ± 12.9 U/L, p=0.03). In this real-world analysis of a large Canadian cohort, patients initiating semaglutide had significant reductions in A1C and weight at three to six months, regardless of prior and concomitant diabetes therapy. Disclosure R.E. Brown: None. A.R. Liu: Employee; Self; Novo Nordisk A/S. R. Mahbubani: Employee; Self; Novo Nordisk Inc. R. Aronson: Research Support; Self; AstraZeneca, Becton, Dickinson and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk Inc., Sanofi, Senseonics. Funding Novo Nordisk Canada Inc.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.004 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".